Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-066886
Filing Date
2025-05-08
Accepted
2025-05-08 16:00:18
Documents
48
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q crdf-20250331.htm   iXBRL 10-Q 1475495
2 EX-31.1 crdf-ex31_1.htm EX-31.1 14371
3 EX-31.2 crdf-ex31_2.htm EX-31.2 14252
4 EX-32.1 crdf-ex32_1.htm EX-32.1 7369
5 EX-32.2 crdf-ex32_2.htm EX-32.2 7250
  Complete submission text file 0000950170-25-066886.txt   6393623

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crdf-20250331.xsd EX-101.SCH 690762
50 EXTRACTED XBRL INSTANCE DOCUMENT crdf-20250331_htm.xml XML 1388306
Mailing Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121
Business Address 11055 FLINTKOTE AVENUE SAN DIEGO CA 92121 858-952-7570
Cardiff Oncology, Inc. (Filer) CIK: 0001213037 (see all company filings)

EIN.: 272004382 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35558 | Film No.: 25925789
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)